Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17227883 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELATSHRKDM4E | |
| SCHEMBL30315348 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELATSHRKDM4E | |
| SCHEMBL17229229 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELATSHRKDM4E | |
| SCHEMBL25201323 | 0.87 | MAOB (0.40) | NFKB1NFKB2RELAKDM4EAR | |
| SCHEMBL17227902 | 0.87 | MAOB (0.40) | NFKB1NFKB2RELAKDM4EAR | |
| SCHEMBL15954244 | 0.87 | MAOB (0.40) | NFKB1NFKB2RELAKDM4EAR | |
| SCHEMBL25190010 | 0.85 | MEN1 (0.39) | NFKB1NFKB2RELAARHSD17B10 | |
| SCHEMBL25193070 | 0.85 | POLB (0.39) | NFKB1NFKB2RELAKDM4EAR | |
| SCHEMBL15953936 | 0.85 | POLB (0.39) | NFKB1NFKB2RELAKDM4EAR | |
| SCHEMBL25194232 | 0.85 | MAOB (0.39) | NFKB1NFKB2RELACYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119842767-A | Recombinant expression vector for synthesizing outer membrane protein of cyanidin-3-O-glucoside, recombinant microorganism and preparation method thereof | 陕西科技大学 | 2025-04-18 | — | — | CN | claimed |
| CN-116656710-A | Application of multidrug resistance transporter MdtH in synthesis of cyanidin-3-O-glucoside | 陕西科技大学 | 2023-08-29 | — | — | CN | claimed |
| US-20040242503-A1 | Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease | ATTENTION LABS INCORPORATED | 2004-12-02 | — | — | US | claimed |
| EP-1267853-B1 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & CA SA (PT) | 2004-09-08 | — | — | EP | claimed |
| CN-1429109-A | Compositions comprising blockers of L-DOPA renal cell transfer for treatment of Parkinson's disease | PORTELA & CA SA (PT) | 2003-07-09 | — | — | CN | claimed |
| EP-1267853-A2 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | Portela & Ca., S.A. (PT) | 2003-01-02 | — | — | EP | claimed |
| WO-2001068065-A9 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & CA SA (PT) | 2002-07-18 | — | — | WO | claimed |
| WO-2001068065-A2 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & COMPANHIA S.A. (PT) | 2001-09-20 | — | — | WO | claimed |
| CN-121895273-A | Preparation method and application of 2-phenyl-2H-chromene compound | 大理大学 | 2026-04-21 | — | — | CN | disclosed |
| CN-121895273-A | Preparation method and application of 2-phenyl-2H-chromene compound | 大理大学 | 2026-04-21 | — | — | CN | disclosed |
| CN-121054755-B | Low-temperature-resistant flow battery electrolyte, preparation method and zinc-bromine flow battery | 西安热工研究院有限公司 | 2026-02-10 | — | — | CN | disclosed |
| CN-121054755-A | Low-temperature-resistant flow battery electrolyte, preparation method and zinc-bromine flow battery | 西安热工研究院有限公司 | 2025-12-02 | — | — | CN | disclosed |
| CN-120025386-A | Preparation method of anthocyanin reference substance | 泰州医药城国科化物生物医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119842767-A | Recombinant expression vector for synthesizing outer membrane protein of cyanidin-3-O-glucoside, recombinant microorganism and preparation method thereof | 陕西科技大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-1181077-A | benzopyran compounds and methods of use thereof | ENDORECHERCHE (CA) | 1998-05-06 | — | — | CN | disclosed |
| WO-1996021440-A9 | METHODS FOR INCREASING THE BIOAVAILABILITY OF BIOLOGICAL ACTIVE AGENTS | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996021440-A1 | METHODS FOR INCREASING THE BIOAVAILABILITY OF BIOLOGICAL ACTIVE AGENTS | ALPHA-THERAPEUTICS, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0348121-B1 | PROCESS FOR THE SYNTHESIS OF ANTHOCYANIDINES AND NOVEL INTERMEDIATES PRODUCED IN SAID PROCESSES | IDB HOLDING S.p.A. (IT) | 1993-04-07 | — | — | EP | disclosed |
| EP-0178633-B1 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0348121-A1 | Process for the synthesis of anthocyanidines and novel intermediates produced in said processes | IDB HOLDING S.p.A. (IT) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242503-A1 | Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease | COMT, DDC, AADAT | NFKB1 2824/4885NFKB2 2785/4885RELA 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.